ly2886721
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01133405)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta-secretase 1INHIBITOR
BACE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly2886721
- ly2886721
- ly2886721
- n-(3-(2-amino-4a,5,7,7a-tetrahydro-4h-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01807026 | Phase 1 | Mar 1, 2013 | Eli Lilly |
| NCT01775904 | Phase 1 | Feb 1, 2013 | Eli Lilly |
| NCT01561430 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2012 | Eli Lilly |
| NCT01534273 | Phase 1 | Feb 1, 2012 | Eli Lilly |
| NCT01367262 | Phase 1 | Jun 1, 2011 | Eli Lilly |
| NCT01227252 | Phase 1 | Dec 1, 2010 | Eli Lilly |
| NCT01133405 | Phase 1 | Jun 1, 2010 | Eli Lilly |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1